검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Vancomycin |
Overview Company | Microbiotica Ltd |
Overview Modality | ANTIBODY |
Overview Target | Melanoma |
Overview Indication | Metastatic Colorectal Adenocarcinoma; Metastatic Small Intestinal Adenocarcinoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | target the reactive oxygen species (ROS) and the A Disintegrin and Metalloproteinase 10 (ADAM10)-alpha-hemolysin (AHL) pathway |
MoA Biomarker | biomarkers, increased lipid peroxidation, depletion of antioxidant defenses, dysregulated cytokine levels, an |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Characterizing the antimicrobial activity of cisplatin against Gram-positive clinical strains: bridging existing gaps.. Multidrug resistant (MDR) bacteria are one of the most important current threats to public health. Therefore, serious concerns were raised about the effectiveness of traditional antibiotics. Cisplatin, a chemotherapeutic agent that is used mainly in cancer treatment, has recently… |
Clinical Primary efficacy | ORR 9% |
Clinical ORR | 9% |
Clinical Result source | ClinicalTrials.gov NCT05225558 |
Clinical Data Tier / Score | A · 35 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Vancomycin |
Overview Company | Microbiotica Ltd |
Overview Modality | ANTIBODY |
Overview Target | Melanoma |
Overview Indication | Metastatic Colorectal Adenocarcinoma; Metastatic Small Intestinal Adenocarcinoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | target the reactive oxygen species (ROS) and the A Disintegrin and Metalloproteinase 10 (ADAM10)-alpha-hemolysin (AHL) pathway |
MoA Biomarker | biomarkers, increased lipid peroxidation, depletion of antioxidant defenses, dysregulated cytokine levels, an |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Characterizing the antimicrobial activity of cisplatin against Gram-positive clinical strains: bridging existing gaps.. Multidrug resistant (MDR) bacteria are one of the most important current threats to public health. Therefore, serious concerns were raised about the effectiveness of traditional antibiotics. Cisplatin, a chemotherapeutic agent that is used mainly in cancer treatment, has recently… |
Clinical Primary efficacy | ORR 9% |
Clinical ORR | 9% |
Clinical Result source | ClinicalTrials.gov NCT05225558 |
Clinical Data Tier / Score | A · 35 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교